Former FDA Commissioner returns to venture capital firm

pharmafile | June 4, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Scott Gottlieb, appointment, pharma 

Dr Scott Gottlieb, former Commissioner for the FDA, has returned to his venture capital background with the announcement that he has been appointed as a Special Partner on the healthcare investment team at New Enterprise Associates (NEA), the same company he left to join the US regulator.

NEA invests in companies across a range of industry disciplines, managing over $20 billion in assets. Dr Gottlieb originally served at the company from 2007 to 2017 as Venture Partner, before stepping up to become 23rd Commissioner of the FDA, holding the role from 2017 to 2019. During his time at the agency, he carved a legacy which saw the introduction of more robust oversight of gene therapies, cell-based medicines, targeted drugs and digital health devices, and the promotion of stricter stances on tobacco, treatment for addiction and e-cigarette use. During his tenure, the agency saw its budget expanded by 20% and broke records for the most new drug approvals in a single year.

“I’m delighted to rejoin the venture capital firm, where I worked for a decade prior to my most recent government service; and help support the innovation economy that’s leveraging science to advance care, improve delivery, and expand consumer choice,” Gottlieb revealed via tweet.

Dr Gottlieb is also an elected member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC. Earlier in his career, Dr Gottlieb also served at the FDA as Deputy Commissioner for Medical and Scientific Affairs, and prior to that he was a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services.

“Throughout his prior 10-year tenure at NEA, Scott’s broad expertise was a tremendous asset for our healthcare practice and portfolio companies,” commented David Mott, General Partner and Head of Healthcare Investing at NEA. “We are proud of his contributions to advancing innovation and increasing the quality of patient care as head of the FDA, and we’re thrilled to have him rejoin NEA, this time as a full-time investing partner. Scott will be based in our Chevy Chase, Maryland office and will be an active investor across the full spectrum of our healthcare activities, with a particular emphasis on biopharma and healthcare services. Scott is an invaluable resource for our entrepreneurs and our investing team as we work together to advance new products and services to better serve patients.”

Related Content

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …

Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA

Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for …

FDA approves LimFlow system for patients with CLTI

LimFlow SA has announced that the US Food and Drug Administration (FDA) has approved its …

Latest content